- Conditions
- Metastatic Breast Cancer
- Interventions
- Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 2 more
Breast Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Breast Cancer. Browse Breast Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 17, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Breast Cancer studies are organized in the registry
Breast cancer listings are usually subtype-specific: receptor status appears directly in titles and condition fields, so subtype terms narrow results far better than stage words alone. Many studies also restrict to either early-stage or metastatic settings, which is visible in the title or eligibility section of the official record.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- fulvestrant, anastrozole
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 856
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more
- Conditions
- Breast Cancer, HER2+ Breast Cancer
- Interventions
- VRP-HER2, Pembrolizumab
- Biological
- Lead sponsor
- Herbert Lyerly
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma of No Special Type
- Interventions
- Biospecimen Collection, Letrozole, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER+ Breast Cancer, Lobular Breast Carcinoma
- Interventions
- Neoadjuvant endocrine therapy
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Breast Neoplasms
- Interventions
- endocrine therapy alone without radiotherapy
- Other
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 50 Years to 69 Years · Female only
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 13
- States / cities
- Stanford, California • New Haven, Connecticut • Maywood, Illinois + 10 more
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Breast Cancer in the Liver
- Interventions
- Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
- Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Cleveland, Ohio • Columbus, Ohio + 1 more
- Conditions
- HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Cancer
- Interventions
- Olaparib, Pembrolizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
- Interventions
- Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 662
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
- Conditions
- Metastatic Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Breast Cancer Metastatic, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Hormone-receptor-positive Breast Cancer
- Interventions
- Abemaciclib, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
About this Breast Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Breast Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Breast Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Breast Cancer.